Nondevelopment of resistance by bacteria during hospital use of povidone-iodine.
Since the bacterial ability to develop resistance against various factors of their surroundings is a well-known phenomenon, resistance against iodine and specifically against povidone-iodine (PVP-I) has been widely investigated. Yet there is little known about bacterial resistance in long-term daily use of disinfectants in continuous ambulatory peritoneal dialysis (CAPD) patients. The aim of our study was to investigate whether on daily use of PVP-I over a period of at least 6 months coagulase-negative staphylococci (CNS)--the predominant infective organisms of peritonitis--developed resistance against PVP-I. At the catheter exit site of 40 CAPD patients we isolated 36 CNS. 23 CNS (CNS + PVP) orginate from patients using PVP-I, 13 CNS (CNS + CI) from patients using sodium hypochlorite (NaOCl) as disinfectant. The strains were biotyped, antibiotic resistance patterns were determined and resistance against PVP-I or NaOCl was calculated as reduction factor using the quantitative suspension test combined with a turbidimetric standardization. Resistance against PVP-I 0.01% and against NaOCl 0.005% was determined at two contact times (30 and 300 s) for each patient group. In addition, we investigated the effects of plasmid loss on sensitivity to PVP-I. Out of 5 multiple-antibiotic-resistant CNS, 3 strains showed no difference in reduction factor against PVP-I before and after curing. There was no significant difference in reduction factor against NaOCl. CNS + PVP were even significantly more sensitive to PVP-I than CNS + Cl. Taken together, our results demonstrate that long-term use of PVP-I does not cause any bacterial resistance in CNS of CAPD patients.
Lanker Klossner
B
B
Department of Internal Medicine, Nephrology, University Hospital of Berne, Switzerland.
Widmer
H R
HR
Frey
F
F
D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use*; D015373:Bacterial Typing Techniques; D002408:Catheters, Indwelling / Q000009:adverse effects; D015169:Colony Count, Microbial; D004202:Disinfectants / Q000008:administration & dosage / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007466:Iodophors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009391:Nephelometry and Turbidimetry; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000295:instrumentation; D010538:Peritonitis / Q000188:drug therapy / Q000382:microbiology*; D010957:Plasmids / Q000187:drug effects; D011206:Povidone-Iodine / Q000008:administration & dosage / Q000627:therapeutic use*; D012973:Sodium Hypochlorite / Q000008:administration & dosage / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000145:classification / Q000187:drug effects* / Q000254:growth & development; D013997:Time Factors
D000891:Anti-Infective Agents, Local; D004202:Disinfectants; D007466:Iodophors; D011206:Povidone-Iodine; D012973:Sodium Hypochlorite